Kraig Biocraft Labs
Kraig Biocraft Laboratories, Inc. develops protein-based fibers using recombinant DNA technology for commercial applications in the textile and specialty fiber industries in the United States. Its primary proprietary fiber technology includes natural and engineered variants of spider silk produced in domesticated mulberry silkworms, as well as uses genetically engineered silkworms that produce sp… Read more
Kraig Biocraft Labs (KBLB) - Total Liabilities
Latest total liabilities as of September 2025: $10.31 Million USD
Based on the latest financial reports, Kraig Biocraft Labs (KBLB) has total liabilities worth $10.31 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kraig Biocraft Labs - Total Liabilities Trend (2009–2024)
This chart illustrates how Kraig Biocraft Labs's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Kraig Biocraft Labs Competitors by Total Liabilities
The table below lists competitors of Kraig Biocraft Labs ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TerrAscend Corp.
OTCQX:TSNDF
|
USA | $459.78 Million |
|
Pricer AB (publ)
PINK:PCRBF
|
USA | $1.02 Billion |
|
Molecular Partners AG
PINK:MLLCF
|
USA | $16.62 Million |
|
ISU Abxis Co. Ltd
KQ:086890
|
Korea | ₩45.29 Billion |
|
Shanghai Jinjiang International Travel Co Ltd
SHG:900929
|
China | $532.93 Million |
|
Sitowise Group Oyj
HE:SITOWS
|
Finland | €153.00 Million |
|
Bank Multiarta Sentosa PT
JK:MASB
|
Indonesia | Rp29.51 Trillion |
|
GSD Holding AS
IS:GSDHO
|
Turkey | TL6.03 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down Kraig Biocraft Labs's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kraig Biocraft Labs's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kraig Biocraft Labs (2009–2024)
The table below shows the annual total liabilities of Kraig Biocraft Labs from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $9.65 Million | +8.00% |
| 2023-12-31 | $8.94 Million | +10.47% |
| 2022-12-31 | $8.09 Million | -2.71% |
| 2021-12-31 | $8.32 Million | +5.95% |
| 2020-12-31 | $7.85 Million | +27.89% |
| 2019-12-31 | $6.14 Million | +35.50% |
| 2018-12-31 | $4.53 Million | +29.81% |
| 2017-12-31 | $3.49 Million | +27.18% |
| 2016-12-31 | $2.74 Million | +24.64% |
| 2015-12-31 | $2.20 Million | +24.75% |
| 2014-12-31 | $1.76 Million | +16.73% |
| 2013-12-31 | $1.51 Million | +24.65% |
| 2012-12-31 | $1.21 Million | +7.44% |
| 2011-12-31 | $1.13 Million | +53.19% |
| 2010-12-31 | $737.00K | -76.99% |
| 2009-12-31 | $3.20 Million | -- |